Pathway analysis of primary central nervous system lymphoma

Blood

Volumn 111, Issue 6, 2008, Pages 3200-3210

  Tun, Han W ^a   Personett, David ^a   Baskerville, Karen A ^a   Menke, David M ^a   Jaeckle, Kurt A ^a   Kreinest, Pamela ^a   Edenfield, Brandy ^a   Zubair, Abba C ^a   O'Neill, Brian P ^b   Lai, Weil R ^c   Park, Peter J ^c   McKinney, Michael ^a,d  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c LABORATORY FOR MOLECULAR MEDICINE   (United States)

^d Department of Molecular Pharmacology and Therapeutics ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPONTIN;

ARTICLE; BIOINFORMATICS; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BIOLOGY; CENTRAL NERVOUS SYSTEM TUMOR; COMPUTER PROGRAM; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; GENOME; LARGE CELL LYMPHOMA; METABOLISM;

CENTRAL NERVOUS SYSTEM NEOPLASMS; COMPUTATIONAL BIOLOGY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SOFTWARE;

EID: 42449093305     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-10-119099     Document Type: Article

References (39)

1. Anthony IC, Crawford DH, Bell JE. B lymphocytes in the normal brain: contrasts with HIV-associated lymphoid infiltrates and lymphomas. Brain. 2003; 126:1058-1067.
2. Braaten KM, Betensky RA. de Leval L, et al. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res. 2003;9:1063-1069.
3. Larocca LM, Gapello D, Rinelli A, et al. The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. Blood. 1998;92:1011-1019.
4. RosenwaldA, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.
5. Camilleri-Broet S, Criniere E, Broet P, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood. 2006;107:190-196.
6. Deangelis LM. Iwamoto FM. An update on therapy of primary central nervous system lymphoma. Hematol Am Soc Hematol Educ Program. 2006:311-316.
7. Rubenstein JL, Fridlyand J. Shen A, et al. Gene expression and angiotropism in primary CNS lymphoma. Blood. 2006;107:3716-3723.
8. Cox WG, Beaudet MP Agnew JY, Ruth JL. Possible sources of dye-related signal correlation bias in two-color DNA microarray assays. Anal Biochem. 2004;331:243-254.
9. Eisen MB, Spellman PT Brown PO Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998;95:14863-14868.
10. Tian L, Greenberg SA. Kong SW, Altschuler J, Kohane IS, Park PJ. Discovering statistically significant pathways in expression profiling studies. Proc Natl Acad Sci U S A. 2005;102:13544-13549.
11. Troyanskaya O, Cantor M, Sherlock G, et al. Missing value estimation methods for DNA microarrays. Bioinformatics. 2001;17:520-525.
12. Baskerville KA, Kent C, Personett D, et al. Aging elevates metabolic gene expression in brain cholinergic neurons. Neurobiol Aging. Prepublished June 7, 2007 as DOI 10.1016/j.neurobiolaging. 2007.04.024.
13. Stephanopoulos G, Hwang D, Schmitt WA, Misra J, Stephanopoulos G. Mapping physiological states from microarray expression measurements. Bioinformatics. 2002;18:1054-1063.
14. Jellinger KA, Paulus W. Primary central nervous system lymphomas: new pathological developments. J Neurooncol. 1995:24:33-36.
15. Paulus W, Jellinger K. Comparison of integrin adhesion molecules expressed by primary brain lymphomas and nodal lymphomas. Acta Neuropathol (Berl). 1993:86:360-364.
16. Rubenstein JL. Treseler P, O'Brien JM. Pathology and genetics of primary central nervous system and intraocular lymphoma. Hematol Oncol Clin North Am. 2005:19:705-717.
17. EI-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M, Rudland PS. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev. 2006:17: 463-474.
18. Weber GF The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta. 2001;1552:61-85.
19. Coppola D, Szabo M, Boulware D, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res. 2004:10:184-190.
20. Junaid A, Moon MC, Harding GE, Zahradka P. Osteopontin localizes to the nucleus of 293 cells and associates with polo-like kinase-1. Am J Physiol Cell Physiol. 2007:292:C919-C926.
21. Chabas D, Baranzini SE, Mitchell D, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science. 2001;294:1731-1735.
22. Johansen JS, Jensen BV, Roslind A, Price PA. Is YKL-40 a new therapeutic target in cancer? Expert Opin Ther Targets. 2007;11:219-234.
23. Kim SH, Das K, Noreen S, Coffman F, Hameed M. Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer. World J Surg Oncol. 2007;5:17.
24. Schlessinger J. Direct binding and activation of receptor tyrosine kinases by collagen. Cell. 1997; 91:869-872.
25. Weiner HL, Huang H, Zagzag D, Boyce H, Lichtenbaum R, Ziff EB. Consistent and selective expression of the discoidin domain receptor-1 tyrosine kinase in human brain tumors. Neurosurgery. 2000;47:1400-1409.
26. Went P. Luglia A, Meier S. Frequent EpCam protein expression in human carcinoma. Human Pathol. 2004;35:122-128.
27. Krishnakumar S, Mohan A, Mallikarjuna K, et al. EpCAM expression in retinoblastoma: a novel molecular target for therapy. Invest Ophthalmol Vis Sci. 2004;45:4247-4250.
28. Smith JR, Braziel RM, Paoletti S, Lipp M, Uguccioni M, Rosenbaum JT. Expression of B-cellattracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood. 2003; 101:815-821.
29. Shi GX, Harrison K, Wilson GL, Moratz C, Kehrl JH. RGS13 regulates germinal center B lymphocytes responsiveness to CXC chemokine ligand (CXCL)12b and CXCL 13. J Immunol. 2002;169: 2507-2515.
30. Teitell MA. The TGLI family of oncoproteins: coactivators of transformation. Nat Rev Cancer. 2005;5:640-648.
31. Chin D, Boyle GM, Williams RM, et al. Alpha B-crystallin, a new independent marker for poor prognosis in head and neck cancer. Laryngoscope. 2005;115:1239-1242.
32. Shi T, Dong F, Liou LS, Duan ZH, NovickAC, Di-Donato JA. Differential protein profiling in renalcell carcinoma. Mol Carcinog. 2004;40:47-61.
33. Niehrs C. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene. 2006:25:7469-7481.
34. Bennaceur-Griscelli A, Bosq J, Koscielny S, et al. High level of glutathione-S-transferase pi expression in mantle cell lymphomas. Clin Cancer Res. 2004:10:3029-3034.
35. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 1994;54: 4313-4320.
36. Ilg EC, Schafer BW, Heizmann CW. Expression pattern of S-100 calcium-binding proteins in human tumors. Int J Cancer. 1996;68:325-332.
37. Torabian S, Kashani-Sabet M. Biomarkers for melanoma. Curr Opin Oncol. 2005;17:167-171.
38. Vostrejs M, Moran PL, Seligman PA. Transferrin synthesis by small cell lung cancer cells acts as an autocrine regulator of cellular proliferation. J Clin Invest. 1988;82:331-339.
39. Habeshaw JA, Lister TA, Stansfeld AG, Greaves MF Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma. Lancet. 1983;1:498-501.